Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol., 31 January 2020
Sec. Pharmacology of Anti-Cancer Drugs

RETRACTED: Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor

Retracted
Xiaoqing Dou&#x;*Xiaoqing Dou1†*Qun Zhou&#x;*Qun Zhou1†*Mingxiao WenMingxiao Wen1Jiangyan XuJiangyan Xu2Yingping ZhuYingping Zhu1Shuzhen ZhangShuzhen Zhang2Xianli XuXianli Xu1
  • 1Department of Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China
  • 2Department of Clinical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China

Citation: Dou X, Zhou Q, Wen M, Xu J, Zhu Y, Zhang S and Xu X (2020) Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor. Front. Pharmacol. 10:1700. doi: 10.3389/fphar.2019.01700

Received: 29 September 2019; Accepted: 31 December 2019;
Published: 31 January 2020; Retracted: 05 January 2023.

Edited by:

Olivier Feron, Université Catholique de Louvain, Belgium

Reviewed by:

Chen Ling, Fudan University, China
Qiang Wang, Nanjing Drum Tower Hospital, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.